Clinical Trials in the USA / NCT06264492
Starting soon
Observational
Delving Into Participation Trends of Scleroderma Clinical Trials
NCT06264492 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Scleroderma
Study summary
Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular demographics.
The study will analyze data from diverse demographic viewpoints to uncover recurring trends that could provide valuable insights for future patients with scleroderma.
Eligibility
Inclusion Criteria:
* Patient has been diagnosed with scleroderma
* Patient has self-identified as planning to enroll in an observational clinical trial
* Patient is a minimum of 18 years or older
Exclusion Criteria:
* Patient is pregnant
* Inability to perform regular electronic reporting
* Patient does not understand, sign, and return consent form
Primary outcome measure(s)
- Rate of patients in clinical research for scleroderma — 3 months
- Number of scleroderma study participants who stay committed until clinical study wraps up — 12 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Power Life Sciences | San Francisco | California |
More Power Life Sciences Inc. trials in the USA
Other trials for the same condition
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Active, not recruiting
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06264492 on ClinicalTrials.gov ↗ ← All trials in the USA